- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal: Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes. (Pubmed Central) - Apr 15, 2022 She underwent seven months of dual anti-HER2 blockade before relapsing cerebrally. Our results suggest that the sequential combination therapy with Trastuzumab, Pertuzumab and Paclitaxel presented in this study, associated with a healthy lifestyle, may be a good management for recurrent HER2-positive breast cancer with pulmonary visceral crisis and severe liver dysfunction.
- |||||||||| Journal: Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. (Pubmed Central) - Apr 13, 2022
Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC.
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
Review, Journal: Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. (Pubmed Central) - Apr 12, 2022 In summary, our study identifies classical complement activation as a significant anti-tumor MOA for T+P therapy that may be functionally enhanced to augment therapeutic efficacy in the clinic. These benefits and risks inform treatment decisions for individuals and recommendations for groups of women.
- |||||||||| Perjeta (pertuzumab) / Roche
Clinical, P1 data, PK/PD data, Journal: A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects. (Pubmed Central) - Apr 7, 2022 In addition, both had good safety in the study. The study shows that pertuzumab injection and Perjeta® had similar bioequivalence, immunogenicity and safety.
- |||||||||| Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Metastases: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 7, 2022 P1b, N=43, Active, not recruiting, The study shows that pertuzumab injection and Perjeta® had similar bioequivalence, immunogenicity and safety. Recruiting --> Active, not recruiting | N=99 --> 43
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 31, 2022 P2, N=216, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2028 | Trial primary completion date: Sep 2020 --> May 2022 Recruiting --> Active, not recruiting
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: EORTC-75111-10114: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (clinicaltrials.gov) - Mar 28, 2022 P2, N=80, Active, not recruiting, Recruiting --> Active, not recruiting Trial completion date: Nov 2021 --> Jun 2022
- |||||||||| Clinical, Review, Journal: How we treat patients with metastatic HER2-positive breast cancer. (Pubmed Central) - Mar 25, 2022
The randomized DESTINY-BREAST03 study compared trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) in patients previously treated with trastuzumab and a taxane...For subsequent lines, trastuzumab duocarmazine, neratinib plus capecitabine or the continuation of trastuzumab with different chemotherapy partners are valid options...For those relapsing between 6 and 12 months after non-pertuzumab-based adjuvant treatment, we recommend first-line THP. Finally, for patients with active brain metastasis, tucatinib-based combination represents a suitable second-line option.
- |||||||||| Herceptin (trastuzumab) / Roche
Review, Journal, IO biomarker: Vaccination against Her-2/neu, with focus on peptide-based vaccines. (Pubmed Central) - Mar 25, 2022 Conversely, these drawbacks could be potentially overcome by vaccination, i.e. an active immunization/immunotherapy approach by activating the patient's own immune system to target cancer, along with inducing immunological memory. This review aims to summarize the main approaches investigated and undertaken for the production of Her-2/neu vaccine candidates, with the main focus on peptide-based vaccines and their evaluation in clinical settings.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Preclinical, Journal: Analytical and pharmacological consequences of the in vivo deamidation of trastuzumab and pertuzumab. (Pubmed Central) - Mar 23, 2022 A good correlation between the non-deamidated concentration results and those of a receptor binding assay indicate a loss of receptor binding for both trastuzumab and pertuzumab along with the deamidation in their CDRs. Deamidated trastuzumab also lost its capability to inhibit the growth of breast cancer cells in a cell-based viability assay, suggesting a relation between the degree of deamidation and pharmacological activity.
- |||||||||| Herceptin (trastuzumab) / Roche
Review, Journal: Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. (Pubmed Central) - Mar 23, 2022 We also review future directions and provide an overview of ongoing clinical trials which include patients with HER2+ brain metastases. With future focus on inclusive clinical trial design, particularly inclusion of patients with brain metastases, optimal strategies for management will be better elucidated.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (clinicaltrials.gov) - Mar 22, 2022 P3, N=437, Active, not recruiting, HER-2/CEP17 ratio and HER-2/cell number ratio were crucial for predicting efficacy. Trial completion date: Dec 2022 --> Dec 2024
- |||||||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial (Hamburg Hall) - Mar 19, 2022 - Abstract #ESMOBC2022ESMO_BC_471; P2 Therefore, the prospective, single-arm, phase II TUXEDO-1 trial investigated T-DXd in HER2-positive BC pts with active BM.Methods TUXEDO-1 included adult pts with HER2-positive BC and newly diagnosed untreated BM or BM progressing after local therapy, prior exposure to trastuzumab and pertuzumab, and no indication for immediate local therapy...The null hypothesis was to be rejected with a type I error rate of 5% and a power of 80% if at least 7 responses were observed.Results As of December 29th, 2021, all 15 pts had received at least one dose of T-DXd (60% progressive BM, 70% prior T-DM1)...Grade 2 interstitial lung disease and a symptomatic drop of left-ventricular ejection fraction were observed in one patient each.Conclusions In the TUXEDO-1 study , T-DXd yielded high intracranial response rates. Data suggest that T-DXd achieves significant therapeutic effects in the central nervous system and should thus be further explored in this context.
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
A Real-World Study on Prevalence of and Outcomes Related to Brain Metastases among Patients with HER2-Positive Metastatic Breast Cancer (mBC) (Exhibition area) - Mar 19, 2022 - Abstract #ESMOBC2022ESMO_BC_383; Median OS was 24 months for all HER2+ patients with BM and 37 months among those without BM at time of mBC diagnosis (Table). Conclusions Results from this real-world study of patients receiving care in community-based oncology clinics indicate that prevalence of BM in HER2+ mBC increases with number of prior lines of treatment and that survival is poorer in this population compared to those without BM.
|